The Chronic Lymphocytic Leukemia Channel on VJHemOnc is an independent medical education platform, supported with funding from AstraZeneca (Diamond), AbbVie (Platinum), BeOne Medicines (Silver) and Lilly (Silver). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
EHA 2017 | Novel therapies in the future of CLL treatment
Peter Hillmen, MBChB, PhD, FRCP, FRCPath, from St James’s University Hospital Leeds, Leeds, UK, provides us an insight into the future of treatments for chronic lymphocytic leukemia (CLL), namely the combinations of novel agents such as ibrutinib and venetoclax with chemotherapy, CAR T-cells and next-generation BTK inhibitors and other novel agents that may exert less toxicity on patients compared to previous drugs. This interview was filmed at the European Hematology Association (EHA) 2017 Annual Congress in Madrid, Spain.
